Application of methods of renal replacement therapy for abolishment of hyperhydration in patients with decompensated chronic heart failure

Slow continuous ultrafiltration (SCUF), continuous veno venous haemofiltration (CVVHF) are alternative to diuretics methods of treatment of patients with chronic heart failure (CHF), edematous syndrome. Patients of both sexes aged 30-82 years with functional class II-IV CHF were included because of...

Full description

Saved in:
Bibliographic Details
Published inKardiologiia Vol. 50; no. 2; p. 30
Main Authors Tabak'ian, E A, Zaruba, A Iu, Miasnikov, R P, Ataullakhanova, D M, Kukharchuk, V V
Format Journal Article
LanguageRussian
Published Russia (Federation) 2010
Subjects
Adult
Aged
Aged, 80 and over
Diuretics - administration & dosage
Diuretics - therapeutic use
Edema, Cardiac - drug therapy
Edema, Cardiac - therapy
Female
Furosemide - administration & dosage
Furosemide - therapeutic use
Heart Failure - drug therapy
Heart Failure - therapy
Hemofiltration
Humans
Length of Stay
Male
Middle Aged
Renal Replacement Therapy - methods
Time Factors
Treatment Outcome
Ultrafiltration
Walking
Weight Loss
Online AccessGet more information

Cover

More Information
Summary:Slow continuous ultrafiltration (SCUF), continuous veno venous haemofiltration (CVVHF) are alternative to diuretics methods of treatment of patients with chronic heart failure (CHF), edematous syndrome. Patients of both sexes aged 30-82 years with functional class II-IV CHF were included because of decompensation of CHF. Randomization: experiment - 19 patients, 3-4 component therapy plus SCUF or CVVHF; control - 3-4 component therapy plus intravenous furosemide. I ñ at baseline, II ñ after compensation of CHF. Delta weight (kg) - experiment -10.1+/-1.08, control -1.92+/-0.83, p=0.00001; Delta left ventricular ejection fraction - experiment +10.09+/-2.26, control +0.52+/-1.14, p=0.0007; pulmonary artery systolic pressure (mm Hg) - experiment -12.32+/-3,43, control -4.05 +/-2.07, p=0.029; Delta 6 min walk test: experiment +304.22+/-39.4, control +91.91+/-23.4, p=0.00003; Delta glomerular filtration rate - experiment -1.16+/-3.23, control +4.44+/-3.68, p=0.85; duration of hospitalization (days) - experiment 17.26+/-1.43, control 17.52+/-1.02, p=0.59. We did not observe complications related to renal replacement therapy. SCUF and CVVHF are safe for patients. In decompensated CHF SCUF and CVVHF provide greater weight reduction and fluid removal than intravenous diuretics, abolish hypervolemia what cause improvement of myocardial contractility.
ISSN:0022-9040